In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the bla_OXA-72 resistance gene

References

• Livermore DM. Has the era of untreatable infections arrived?. J Antimicrob Chemother 2009;64:i29–36.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;7:1791–8.
   Google Scholar
• Majewski P, Sacha PT, Wieczorek P, Ojdana D, Michalska AD, Tryniszewska E. New Delhi metallo- β-lactamases—the dawn of post-antibiotic era?. Prog Health Sci 2012;2:153–60.
   Google Scholar
• Jane R, Danziger H. Multidrug resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004;38:1449–59.
   PubMedGoogle Scholar
• Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71–93.
   PubMed Web of Science ®Google Scholar
• Wieczorek P, Sacha PT, Hauschild T, Zorawski T, Krawczyk M, Tryniszewska E. Multidrug-resistant Acinetobacter baumannii— the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem Cytobiol 2008;46:257–67.
   PubMed Web of Science ®Google Scholar
• Bakour S, Touati A, Sahli F, Ameur AA, Haouchine D, Rolain JM. Antibiotic resistance determinants of multidrug-resistant Acinetobacter baumannii clinical isolates in Algeria. Diagn Microbiol Infect Dis 2013;76:529–31.
   PubMedGoogle Scholar
• Strateva T, Markova B, Marteva-Proevska Y, Ivanova D, Mitov I. Widespread dissemination of multidrug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase and ArmA 16S ribosomal RNA methylase in a Bulgarian university hospital. Braz J Infect Dis 2012;16:307–10.
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007;20:440–58.
   PubMed Web of Science ®Google Scholar
• Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, et al. Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One 2012;7:e37788.
   PubMedGoogle Scholar
• Kempf M, Rolain JM, Diatta G, Azza S, Samb B, Mediannikov O, et al. Carbapenem resistance in Acinetobacter baumannii in Senegal: the paradigm of a common phenomenon in natural reservoirs. PLoS One 2012;7: e39495.
   PubMed Web of Science ®Google Scholar
• Superti SV, Martins Dde S, Caierao J, Soares Fda S, Prochnow T, Zavascki AP. Indications for carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration. Rev Inst Med Trop Sao Paulo 2009;51:111–3.
   PubMedGoogle Scholar
• Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske GC, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Li J, Nation RL, Superti SV, Barth AL, Lutz L, et al. Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organism from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug. J Clin Microbiol 2009;47:3064–5.
   PubMedGoogle Scholar
• Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 2008;60:421–7.
   PubMed Web of Science ®Google Scholar
• Zavacski AP, Li J. Intravenous colistimethate for multidrug-resistant Gram-negative bacteria. Lancet Infect Dis 2008;8: 403–5.
   PubMedGoogle Scholar
• Reis AO, Deise Luz AM, Tognim MC, Sader HS, Gales AC. Polymyxin-resistant Acinetobacter spp. isolates: what is next?. Emerg Infect Dis 2003;9:1025–7.
   PubMed Web of Science ®Google Scholar
• Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010;23:14–34.
   PubMed Web of Science ®Google Scholar
• Sanders WE Jr. Rifampin. Ann Intern Med 1976;85:82–6.
   PubMedGoogle Scholar
• Pachon-Ibanez ME, Fernandez-Cuenca F, Docobo-Perez F, Pachon J, Pascual A. Prevention of rifampicin resistance in Acinetobacter baumannii in experimental pneumonia murine model, using rifampin associated with imipenem or sulbactam. J Antimicrob Chemother 2006; 58:689–92.
   PubMed Web of Science ®Google Scholar
• The European Committee of Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin Microbiol Infect 2003;9:ix–xv.
   Google Scholar
• The European Committee of Antimicrobial Susceptibility testing (EUCAST), Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1. EUCAST; 2013.
   Google Scholar
• Soussy CJ. Recommandations. Comité de l’Antibiogramme de la Société Française de Microbiologie; 2012. Available at: www.sfm-microbiologie.org/UserFiles/file/CASFM/CASFM_2012.pdf (accessed 30 June 2013).
   Google Scholar
• Yin XL, Hou TW, Xu SB, Ma CQ, Yao ZY, Li W, et al. Detection of drug resistance-associated genes of multidrug-resistant Acinetobacter baumannii. Microb Drug Resist 2008;14:145–50.
   PubMedGoogle Scholar
• Koeleman JG, Sttoof J, Van Der Bijl MW, Vandenborucke-Grauls CM, Savelkoul PH. Identification of epidemic strains of Acinetobacter baumannii by integrase gene PCR. J Clin Microbiol 2001;39:8–13.
   PubMedGoogle Scholar
• Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006;27:224–8.
   PubMed Web of Science ®Google Scholar
• Tan YT, Ng LS, Tan E, Huang G. In vitro effects of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;60:421–3.
   PubMed Web of Science ®Google Scholar
• The European Committee of Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000;6:503–8.
   PubMedGoogle Scholar
• Corbella X, Montero A, Pujol MI, Dominguez MA, Ayats K, Argerich MJ, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000;38:4086–95.
   PubMed Web of Science ®Google Scholar
• Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233–9.
   PubMed Web of Science ®Google Scholar
• Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007;30:537–40.
   PubMed Web of Science ®Google Scholar
• Wolff M, Joly-Guilou ML, Farinotti R, Carbon C. In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999;43:1406–11.
   PubMed Web of Science ®Google Scholar
• Montero A, Ariza J, Corbella X, Domenech A, Carbellos C, Ayats J, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54:1085–91.
   PubMed Web of Science ®Google Scholar
• Sabbals M, Pujol M, Tubau F, Pena C, Montero A, Dominguez MA, et al. Rifampin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2005;58:697–700.
   Google Scholar
• Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 2009;33:33–9.
   PubMed Web of Science ®Google Scholar
• Pachon-Ibanez ME, Docobo-Perez F, Lopez-Rojas R, Dominguez-Herrera J, Jimenez-Mejias ME, Garcia-Curiel A, et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:1165–72.
   PubMed Web of Science ®Google Scholar
• Clock SA, Tabibi S, Alba L, Kubin CJ, Whittier S, Saiman L. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2013;76:343–6.
   PubMedGoogle Scholar
• Rodriguez CH, De Ambrosio, A, Bajuk M, Spinozzi M, Nastro M, Bombicino K, et al. In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries 2010;29:164–7.
   Google Scholar
• Pachon-Ibanez ME, Docobo-Perez F, Jimenez-Mejias ME, Ibanez-Martinez J, Garcia-Curiel A, Pichardo C, et al. Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains. Eur J Clin Microbiol Infect Dis 2011;30:895–901.
   PubMedGoogle Scholar
• Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006;58:916–29.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013;57:349–58.
   PubMed Web of Science ®Google Scholar